This Administrative Core A will serve to coordinate and direct the operation of the HIVRAD AI061734 grant. Its main functions are to maintain scientific and managerial oversight over the projects and cores and to ensure that the HIVRAD activities synergize with other AIDS vaccinerelated activities at Duke and nationally. Most importantly, Core A will ensure that the scientific projects and cores make steady progress toward meeting project milestones. Meetings with the External Advisory Committee, travel arrangements to offsite NIAID-sponsored meetings and programs, fiscal management, internal scientific conferences, and preparation of periodic research reports and related manuscripts will be organized through this administrative unit, operating through the direction of the Principal Investigator, Dr. Barton F. Haynes, the IPCAVD administrator, Mr. Evan Ellis-Rayner, and the project development coordinator, Mr. Larry Freeman.
The Specific Aims of Administrative Core A are:
Aim 1 : Coordinate and direct the communications, financial management, and operations of the HIVRAD grant team.
Aim 2 : Organize and manage the milestones and timelines of HIV-1 centralized gene evaluation and selection.
Aim 3 : Manage and coordinate gene synthesis and peptide production purchasing process.
Aim 4 : Manage and coordinate the HIVRAD early transmission isolate working group.
Aim 5 : Coordinate and manage the HIVRAD External Advisory Committee, travel arrangements to off-site Ml AID Sponsored meetings, management and preparation of reports and non-competitive HIVRAD renewals.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI061734-05
Application #
7758564
Study Section
Special Emphasis Panel (ZAI1-EC-A (M2))
Project Start
2009-02-01
Project End
2010-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
5
Fiscal Year
2009
Total Cost
$193,407
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Pincus, Seth H; Song, Kejing; Maresh, Grace A et al. (2017) Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins. J Virol 91:
Pincus, Seth H; Song, Kejing; Maresh, Grace A et al. (2017) Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. J Virol 91:
Go, Eden P; Liao, Hua-Xin; Alam, S Munir et al. (2013) Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J Proteome Res 12:1223-34
Liao, Hua-Xin; Chen, Xi; Munshaw, Supriya et al. (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 208:2237-49
Kirchherr, Jennifer L; Hamilton, Jennifer; Lu, Xiaozhi et al. (2011) Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology 409:163-74
Go, Eden P; Hewawasam, Geetha; Liao, Hua-Xin et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85:8270-84
Barouch, Dan H; O'Brien, Kara L; Simmons, Nathaniel L et al. (2010) Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319-23
Lu, Xiaozhi; Hora, Bhavna; Cai, Fangping et al. (2010) Generation of random mutant libraries with multiple primers in a single reaction. J Virol Methods 167:146-51
Tomaras, Georgia D; Haynes, Barton F (2010) Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS 5:421-7
Salazar-Gonzalez, Jesus F; Salazar, Maria G; Keele, Brandon F et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206:1273-89

Showing the most recent 10 out of 27 publications